Clinical Edge Journal Scan

Family history of breast cancer in first-degree relatives may increase risk for certain cancers in men


 

Key clinical point: Men with a family history of breast cancer (FHBC) in either mother or sister are at a higher risk of developing pancreatic, thyroid, prostate, and breast cancers than men without FHBC and, therefore, may need more vigilant cancer surveillance.

Major finding: An FHBC in both mother and sister was associated with an increased overall cancer risk (hazard ratio [HR] 1.69; 95% CI 1.11-2.57), whereas an FHBC in either mother or sister significantly increased the risk of developing pancreatic cancer (HR 1.35; 95% CI 1.07-1.70), breast cancer (HR 3.03; 95% CI 1.13-8.17), thyroid cancer (HR 1.33; 95% CI 1.12-1.56), and prostate cancer (HR 1.28; 95% CI 1.13-1.44).

Study details: Findings are from a population-based study including 2,734,889 men aged ≥40 years, of which 69,124 men had a FHBC in their mother or sister and 276,496 men had no history of cancer in any of their first-degree relatives.

Disclosures: This study was supported by a National Research Foundation of Korea grant. The authors declared no conflicts of interest.

Source: Song H, Jung YS, et al. Increased risk of pancreatic, thyroid, prostate and breast cancers in men with a family history of breast cancer: A population-based study. Int J Cancer. 2023 (May 29). doi: 10.1002/ijc.34573

Recommended Reading

Phase 3 shows promising activity of capivasertib-fulvestrant combo in HR+/HER2− advanced BC
MDedge Hematology and Oncology
HR+/ERBB2+ early BC: Excellent pCR rate with de-escalated neoadjuvant paclitaxel plus trastuzumab and pertuzumab
MDedge Hematology and Oncology
Simultaneous integrated boost noninferior to sequential boost in phase 3 in early BC
MDedge Hematology and Oncology
18F-labeled fluorodeoxyglucose PET-CT detects more distant metastases than conventional staging in locally advanced BC
MDedge Hematology and Oncology
Presence of breast cancer or other cancers in first-degree relatives increases risk for ER-subtypes of BC
MDedge Hematology and Oncology
Surgery may improve outcomes in de novo HER2+ metastatic inflammatory BC
MDedge Hematology and Oncology
Adjuvant capecitabine is remarkably well tolerated in the real world in patients with TNBC
MDedge Hematology and Oncology
Meta-analysis demonstrates association between aspirin intake and reduced BC risk
MDedge Hematology and Oncology
Atypical hyperplasia at surgical margins need not be re-excised in BC patients undergoing BCS and NAC
MDedge Hematology and Oncology
Oral apatinib-etoposide combo may be administered in pretreated advanced TNBC
MDedge Hematology and Oncology